Nutritional influences can have a profound effect on thyroid metabolism. For example, iodine deficiency in areas where cereal grain crops are grown on iodine-deficient soil will impair thyroid metabolism because this mineral is essential for formation of thyroid hormones. Recently an important link has been shown between selenium deficiency and hypothyroidism. Again, cereal grain crops grown on selenium-deficient soil will contain relatively low levels of selenium. While commercial pet food manufacturers compensate for variations in basal ingredients by adding vitamin and mineral supplements, it is difficult to determine optimum levels for so many different breeds of dogs having varying genetic backgrounds and metabolic needs. The selenium-thyroid connection has significant clinical relevance, because blood levels of total and free T4 rise with selenium deficiency. However, this effect does not get transmitted to the tissues as evidenced by the fact that blood levels of the regulatory thyroid-stimulating hormone (TSH) are also elevated or unchanged. Thus, selenium-deficient individuals showing clinical signs of hypothyroidism could be overlooked on the basis that blood levels of T4 hormones appeared normal. The selenium issue is further complicated because chemical antioxidants can impair the bioavailability of vitamin A, vitamin E and selenium, and alter cellular metabolism by inducing or lowering cytochrome p-450, glutathione peroxidase (a selenium-dependent enzyme), and prostaglandin levels. As manufacturers of many premium pet foods began adding the synthetic antioxidant, ethoxyquin, in the late 1980's, its effects, along with those of other chemical preservatives (BHA BHT), are surely detrimental over the long term. The way to avoid this problem is to use foods preserved with natural antioxidants such as vitamin E and vitamin C.
Combining viral antigens, especially those of modified live virus (MLV) type which multiply in the host, elicits a stronger antigenic challenge to the animal. This is often viewed as desirable because a more potent immunogen presumably mounts a more effective and sustained immune response. However, it can also overwhelm the immunocompromised, or even a healthy host, that is continually bombarded with other environmental stimuli and has a genetic predisposition that promotes adverse response to viral challenge. This scenario may have a significant effect on the recently weaned young puppy that is placed in a new environment. Furthermore, while the frequency of vaccinations is usually spaced over a 2-3 week span, some veterinarians have advocated vaccination once a week in stressful situations. To me, this practice makes no sense from a scientific or medical perspective. While young puppies exposed this frequently to vaccine antigens may not demonstrate overt adverse effects, their relatively immature immune systems may he temporarily or more permanently harmed from such antigenic challenges. Consequences in later life may be the increased susceptibility to chronic debilitating diseases. Some veterinarians trace the increasing current problems with allergic and immunological diseases to the introduction of MLV vaccines some 20 years ago. While other environmental factors no doubt have a contributing role, the introduction of these vaccine antigens and their environmental shedding may provide the final insult that exceeds the immunological tolerance threshold of some individuals in the pet population.
Manufacturers of MLV combination vaccines recommend using the same dose for animals of all ages and different sizes. It has never made any sense to vaccinate toy and giant breed puppies (to choose two extremes) with the same vaccine dosage. While these products provide sufficient excess of antigen for the average sized animal, it is likely to be either too much for the toy breeds or too little for the giant breeds. In addition, combining certain specific viral antigens such as distemper with adenovirus 2 (hepatitis) has been shown to influence the immune system by reducing lymphocyte numbers and responsiveness.
Relatively little attention has been paid to the hormonal status of the patient at the time of vaccination. While veterinarians and vaccine manufacturers are aware of the general rule not to vaccinate animals during any period of illness, the same principle should apply to times of physiological hormonal change. This is particularly important because of the known role of hormonal change alone with infectious agents in triggering autoimmune disease. Therefore, vaccinating animals at the beginning of, during, or immediately after an estrous cycle is unwise, as would he vaccinating animals during pregnancy or lactation. In this latter situation, adverse effects can accrue not only to the dam but also because a newborn litter is exposed to shed vaccine virus. One can even question the wisdom of using MLV vaccines on adult animals in the same household because of exposure of the mother and her litter to shed virus. Recent studies with MLV heroes virus vaccines in cattle have shown them to induce necrotic changes in the ovaries of heifers that were vaccinated during estrus. The vaccine strain of this virus was also isolated from control heifers that apparently became infected by sharing the same pasture with the vaccinates. Furthermore, vaccine strains of these viral agents are known to be causes of abortion and infertility following herd vaccination programs. If one extrapolates these findings from cattle to the dog, the implications are obvious.
Most single and combination canine vaccines available today are of MLV origin. This is based primarily on economic reasons and the belief that they produce more sustained protection. A long-standing question remains, however, concerning the comparative safety and efficacy of MLV versus killed (inactivated) virus vaccines. A recent examination of the risks posed by MLV vaccines concluded that they are intrinsically more hazardous than inactivated products. The residual virulence and environmental contamination resulting from the shedding of vaccine virus is a serious concern. More importantly, the ability of new infective agents to develop and spread poses a threat to both wild and domestic animal populations. The controversy in weighing the risks and benefits of MLV versus killed vaccines is building. Vaccine manufacturers seek to achieve minimal virulence (infectivity) while retaining maximal immunogenicity (protection). This desired balance may he relatively easy to achieve in clinically normal, healthy animals but may be problematic for those with even minor immunologic deficit. The stress associated with weaning, transportation, surgery, subclinical illness, and a new home can also compromise immune function. Furthermore, the common viral infections of dogs cause significant immunosuppression. Dogs harboring latent viral infections may not be able to withstand the additional immunological challenge induced by MLV vaccines. The increase in vaccine-associated distemper and parvovirus diseases are but two examples of this potential. So -- why are we causing disease by weakening the immune system with frequent use of combination vaccine products? After all vaccines are intended to protect against disease. It is well-recognized by experts in the field that a properly constituted killed vaccine is always preferable to one of MLV origin. Killed vaccines do not replicate in the vaccinated animal, do not carry the risk of residual virulence and do not shed attenuated viruses into the environment. On the other hand, MLV vaccines are capable of stimulating a more sustained protective response. So what does the future hold here? Veterinarians, scientists, breeders and owners need to voice their concern and discontent with the present industrial vaccine practices. We need to urge manufacturers to seek alternatives. Even if killed vaccines are proven to be somewhat less efficacious (produce lower levels or less sustained protection) than MLV products, they are more safe. All killed vaccines on the market today have passed current efficacy and safety standards in order to be licensed for use by the USDA. The issue is to what extent being more effective elicits a benefit rather than a risk. The future will evolve new approaches to vaccination including sub-unit vaccines, recombinant vaccines using DNA technology, and killed products with new adjuvants to boost and prolong protection. These are not simple solutions to a problem, however, because early data from recombinant vaccines against some human and mouse viruses have shown potentially dangerous side effects by damaging T-lymphocytes. Contributing factors were shown to be the genetic background of the host, the time or dose of infection, and the makeup of the vaccine. We are obviously still a long way from producing a new generation of improved and safe vaccines. In the meantime, we need to return to using killed products whenever they are available and should consider giving them more often (twice yearly rather than annually) for high-risk exposure situations. Vaccines, while necessary and generally safe and efficacious, can be harmful or ineffective in selected situations.
Proper regulation of cellular activity and metabolism is essential to normal body function. Cell division is a process under tight regulatory control. The essential difference between normal and tumor or cancerous cells is a loss of growth control over the process of cell division. This can result from various stimuli such as exposure to certain chemicals, viral infection, and mutations, which cause cells to escape from the constraints that normally regulate cell division. Proliferation of a cell or group of cells in an uncontrolled fashion eventually gives rise to a growing tumor or neoplasm. Of course, tumors can he both benign (a localized mass that does not spread) or malignant (cancerous), in which the tumor grows and metastasizes to many different sites via the blood or lymph.
Tumor cells also express a variety of proteins called "neoantigens" on their surface, and many of these are different from antigens found on normal cells. These new or altered proteins are recognized as foreign by the immune system, and so trigger an immunological attack. There are a large number of them known as tumor-specific or tissue-specific antigens, whereas others recognize the blood group systems, histocompatibility complex, and viruses. The situation in cancer is complex because not only can immunologically compromised individuals become more susceptible to the effects of cancer-producing viral agents and other chemical carcinogens, the cancer itself can be profoundly immunosuppressive. The form of immunosuppression usually varies with the tumor type. For example, lymphoid tumors (lymphomas and leukemia) tend to suppress antibody formation, whereas tumors of T-cell origin generally suppress cell-mediated immunity. In chemically induced tumors, immunosuppression is usually due to factors released from the tumor cells or associated tissues. The presence of actively growing tumor cells presents a severe protein drain on an individual which may also impair the immune response. Blocking factors present in the serum of affected animals exist which can cause enhancement of tumor growth. Additionally, immunosuppression in tumor-bearing animals can be due to the development of suppressor cells.
The body also contains a group of complimentary factors that provide a protective effect against tumors and other immunologic or inflammatory stresses. These are mixtures of proteins produced by T-cells and are referred to as "cytokines." Cytokines include the interleukins, interferons, tumor-necrosis factors, and lymphocyte-derived growth factors. Recent studies have shown that normal levels of zinc are important to protect the body against the damaging effects of the specific cytokine, tumor-necrosis factor (TNF). Inadequate levels of zinc have been shown to promote the effect of TNF in disrupting the normal endothelial barrier of blood vessels. This could have a significant effect in promoting the metastasis of tumor cells to different sites, thereby hastening the spread and growth of a particular cancer.
Currently shout 15% of human tumors are known to have viral causes or enhancement. Viruses also cause a number of tumors in animals and no doubt the number of viruses involved will increase as techniques to isolate them improve. The T-cell leukemias of humans and animals are examples of those associated with retroviral infections. This same class of viruses has been associated with the production of autoimmunity and immunodeficiency diseases. The recent isolation of a retrovirus from a German Shepherd with T-cell leukemia exemplifies the potential role of these agents in producing leukemia and lymphomas in the dog.
The increased prevalence of leukemia and lymphomas in the Golden Retriever and several other breeds is a case in point. Similarly, there has been an increase in the prevalence of hemangiosarcomas (malignant tumors of the vascular endothelium) primarily in the spleen, but also in the heart, liver and skin. They occur most often in middle age or older dogs of medium to large breeds. The German Shepherd dog is the breed at highest risk, but other breeds including the Golden Retriever and Vizsla have shown a significantly increased incidence, especially in certain families. This suggests that genetic and environmental factors play a role. It is tempting to speculate that environmental factors that promote immune suppression or dysregulation contribute to failure of immune surveillance mechanisms. These protect the body against the infectious and environmental agents which induce carcinogenesis and neoplastic change.
As alluded to above, an adequate nutritional state is important in managing a variety of inherited and other metabolic diseases as well as for a healthy immune system. Examples where nutritional management is important in inherited disorders include: adding ingredients to the diet to make it more alkaline for Miniature Schnauzers with calcium oxalate bladder or kidney stones; use of the vitamin A derivative, etretinate in Cocker Spaniels and other breeds with idiopathic seborrhea of the skin; management with drugs and diet of diseases such as diabetes mellitus and the copper-storage disease prevalent in breeds like the Bedlington Terrier, West Highland White Terrier, and Doberman Pinscher; and treatment of vitamin B-12 deficiency in Giant Schnauzers. Other nutritional influences include the vitamin K-dependent coagulation defect elicited in Devon Rex cats following vaccination; hip dysplasia in puppies fed excessive calories; osteochondritis dissecans in dogs fed high levels of calcium; and hypercholesterolemia in inbred sled dogs fed high fat diets.
Nutritional factors that play an important role in immune function include zinc, selenium and vitamin E, vitamin B-6 (pyridoxine),and linoleic acid. Deficiencies of these compounds impair both circulating (humoral) as well as cell-mediated immunity. The requirement for essential nutrients increases during periods of rapid growth or reproduction and also may increase in geriatric individuals, because immune function and the bioavailability of these nutrients generally wanes with aging. As with any nutrient, however, excessive supplementation can lead to significant clinical problems, many of which are similar to the respective deficiency states of these ingredients. Supplementation with vitamins and minerals should only be given with the advice of a professional nutritionist and should not be viewed as a substitute for feeding premium quality fresh and/or commercial dog foods.
Ackerman L. Tile benefits of enzyme therapy Veterinary Forum, October: 4, 5, and 6, 1993.
Berry M.J. Larsen P.R. The role of selenium in thyroid hormone action. Endocrine Reviews, 13 (2): 207-219, 1992.
Cargill J. Thorpe-Vargas S. Feed that dog. Parts IV-VI.Dog World, 78 (10-12): 36-42, 28-31, 36-41, 1993.
Dodds W.J. Autoimmune thyroid disease. Dog World, 77 (4): 3640, 1992.
Dodds W.J. Genetically based immune disorders: Autoimmune diseases. Parts 1-3. Veterinary Practice STAFF 4 (1, 2, and 3): 8-10, 1, 26-31, 35-37, 2.
Dodds W.J. Immune deficiency diseases: Genetically based immune disorders, Part 4. Veterinary Practice STAFF, 4 (5): 19-21, 1992.